Nuformix Share Discussion Threads

[georgeo1] 21/4/2021 09:26

I do but moving investments around to make enough then back in.

[billthebank] 21/4/2021 09:20

Not sure!!Researching it though

[escapetohome] 21/4/2021 09:09

Im back in too!! Are you?

[billthebank] 21/4/2021 09:09

Is this worth researching. Curious!

[for fx sake] 21/4/2021 08:58

I thought you had 'sticky fingers' Georgeo, especially after all those posts you made about the glowing prospects of the company.

[georgeo1] 21/4/2021 08:28

Held long until the recent selling when it dropped, now back in again regretfully at a higher premium should stay and hold on.

[billthebank] 21/4/2021 08:18

Surely eventually NFX has to bounce?

[carlisle44] 20/4/2021 16:29

Is someone shuffling the pack? Large turnover in shares traded today

[maytrees] 20/4/2021 13:13

No Royalalbert but the share price being so low s/he must be almost out imho.

[royalalbert] 20/4/2021 13:12

Maytrees any idea how many the seller may have left.

[maytrees] 20/4/2021 13:03

Odd though with so many buys that the share price is not rising again. Still with FTSE100 down c.80 points one can be thankful for small NFX gain
Edit: further small gain as I typed.

[soupdragon55] 09/4/2021 20:09

And don't get excited by Covid links, NFX have said this is not a priority.

[soupdragon55] 09/4/2021 20:08

NXP004 won't go to Oxilio, the company has said so. It tells you what the plan is in the Allenby research note you posted a link to.

[georgeo1] 09/4/2021 18:54

SNG001 NXP004 OXL001 maybe OXL004

[georgeo1] 09/4/2021 18:43

COVID-19East Texas researcher receives grant to continue work on novel drug for COVID-19-related lung diseaseUT Health Science Center in Tyler (Source: Blake Holland/KLTV)By UT Health Science Center at Tyler | April 1, 2021 at 7:01 AM CDT - Updated April 1 at 8:28 AMTYLER, Texas (KLTV) - The University of Texas Health Science Center at Tyler (UTHSCT) researcher Dr. Sreerama Shetty, a cellular and molecular biology professor, has received a two-year Department of Defense (DoD) grant for nearly $300,000 to continue research on a novel intervention therapy he and his research team have developed for COVID-19-related lung disease."Our research has a strong potential of yielding a new, safe, convenient and effective intervention for patients with COVID-19 due to infection caused by coronavirus 2 (CoV-2)," Shetty said. Patients with acute lung injury (ALI) from COVID-19 often die due to acute lung inflammation that can lead to alveolar damage and organ failure. The CoV-2 targets ACE-2 proteins lining the surface of human cells, including the alveolar cells in the lungs, causing ALI and alveolar epithelial cell death and lung scarring, making a lack of air exchange life threatening.Shetty's research identified a specific peptide, called LTI-03 (also called CSP7), that inhibits alveolar epithelial cell lung injury, including ALI due to sepsis."LTI-03 is well tolerated, can be delivered systemically or via the airway in liquid formulation or micronized dry powder form," Shetty said. "We believe LTI-03 can mitigate ALI associated with COVID-19. Our research will test the efficacy of systemically and airway-delivered LTI-03 against alveolar epithelial cell damage and acute lung injury."Shetty's research will determine whether systemically delivered LTI-03 improves overall survival by inhibiting ALI due to CoV-2 infection and will determine whether better efficacy is achieved by airway inhalation using standard lung function, CT imaging, blood oxygenation, lung viral load, biochemical and histological markers and survival endpoints."Our grant proposal caters to the aggregate strengths of the team in drug discovery, formulation, airway delivery and virology," Shetty said.LTI-03 could be a potential treatment for chronic lung disease called idiopathic pulmonary fibrosis (IPF) that causes progressive lung scarring primarily in adults age 65 and older. With no known cure, fatality is generally three to five years following diagnosis. LTI-03 administered as an inhalant is entering clinical safety trials in Ireland and could cause a worldwide paradigm shift in the treatment of lung fibrosis."If the clinical trials are successful, LTI-03 as an inhalant could become the signature career work of my lifetime," Shetty said.Initial evidence suggests that LTI-03 reverses lung fibrosis in multiple preclinical models, including human IPF tissues, reduces fluid buildup in the lungs that causes life-threatening pneumonia and restores the survival of damaged lung lining cells. IPF causes about 40,000 deaths annually.Antifibrotic drugs approved in 2014 to treat IPF only decelerated the progression of fibrosis, buying patients more time, but LTI-03 as an inhalation therapy holds promise to return patients to healthier lung function by sustaining the survival of damaged lung lining cells and targeting a different cellular signaling pathway than previous pharmaceutical approaches.UTHSCT attracts some of the top researchers from around the world to its 150,000-square-foot research facility in Tyler, Texas, where new medications, protocols and cures are developed. Researchers have earned nearly $300 million in grant-funded research to offer hope to patients in need.Copyright 2021 KLTV. All rights reserved.

[for fx sake] 09/4/2021 13:31

It's holding up rather well today despite the dumpers' best efforts.

[georgeo1] 09/4/2021 12:20

Just waiting for a tick up for a blue day to start off next week with a bang.

[georgeo1] 09/4/2021 11:08

NEWSFLOWOver the next 12-18 months there are a number of possible events on the horizon:– Initiation of the feasibility studies on NXP002 in Q2 2021– OutcomedecisiononOxiliooptiononNXP001.– News on patent filing outcomes, strategic path and partnering for NXP004 in oncology.– Outcome of Innovate UK Grant Application for NXP002 in Q1 2021.– Potential completion (subject to funding) of Phase I ready package for NXP002by H1 2022.– Partneringnewsacrossthepipeline.– Corporate: FY results 12 months ended 31 March 2021 – date estimated July/August.

[georgeo1] 09/4/2021 11:06

NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in upfront and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset: from feasibility up to the full Phase I ready GLP package, assuming successful outcomes and based on recent precedent. We illustrate a range of deal metrics in IPF to support our assumptions. Industry precedent shows that once a robust patent position is built, even early stage IPF assets are attracting significant deals in the indication. While pipelines are filling out, the novel approach, acute need and the inhaled route of administration are key factors that can differentiate NXP002. This from recent Allenby Capital report.

[spurs90] 09/4/2021 11:03

Yes it has

22 March 2021

Nuformix plc

("Nuformix", the "Company" or the "Group")



NXP001 (Oncology) - Exercise of Option by Oxilio



London, UK - 22 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that Oxilio Ltd ("Oxilio") has exercised its option to acquire a licence for NXP001 (a proprietary new form of aprepitant) for oncology indications.



· On 23 September 2020, Nuformix granted an exclusive option to Oxilio, a private pharmaceutical development company, to license NXP001 globally for oncology indications. This triggered the first upfront payment and the option period ran until 23 March 2021



· Nuformix and Oxilio will now work together to finalise a global licensing agreement for NXP001. Once this has been agreed, this will trigger a second undisclosed upfront payment, payable to Nuformix. Under this agreement, Nuformix will license its patent estate and know-how on NXP001 in return for development milestone payments and a royalty on any future net sales, capped at £2m per annum

[georgeo1] 09/4/2021 10:59

Has a global licensing agreement been reached with Oxilio, which expired in March?It was six months since September last year, must be waiting for that news at least.